SOHM, Inc. Shares Groundbreaking Findings in ABBIE Technology
SOHM Inc (OTC PINK:SHMN) has announced significant developments in their ABBIE Technology, revealing a strategic pivot in their business model. The company is transitioning from selling ABBIE kits for independent use to establishing a licensing model, leveraging their global Intellectual Property portfolio.
The company's breakthrough findings indicate that ABBIE technology features unique traceability capabilities absent in competing technologies, potentially streamlining FDA approval processes and enhancing therapy safety. SOHM is currently in technical diligence discussions with both small innovators and major pharmaceutical companies, focusing on applications in CAR-T therapy, cancer drug development, and gene therapy.
The company plans to publish these findings in Q2 2025 and will organize platform seminars to showcase the technology's potential in revolutionizing cancer treatment.
SOHM Inc (OTC PINK:SHMN) ha annunciato sviluppi significativi nella loro tecnologia ABBIE, rivelando un cambiamento strategico nel loro modello di business. L'azienda sta passando dalla vendita di kit ABBIE per uso indipendente all'istituzione di un modello di licenza, sfruttando il loro portafoglio globale di Proprietà Intellettuale.
I risultati innovativi dell'azienda indicano che la tecnologia ABBIE presenta capacità uniche di tracciabilità assenti nelle tecnologie concorrenti, potenzialmente semplificando i processi di approvazione della FDA e migliorando la sicurezza delle terapie. SOHM è attualmente in discussioni di due diligence tecnica con innovatori di piccole dimensioni e grandi aziende farmaceutiche, concentrandosi su applicazioni nella terapia CAR-T, nello sviluppo di farmaci contro il cancro e nella terapia genica.
L'azienda prevede di pubblicare questi risultati nel secondo trimestre del 2025 e organizzerà seminari sulla piattaforma per mostrare il potenziale della tecnologia nel rivoluzionare il trattamento del cancro.
SOHM Inc (OTC PINK:SHMN) ha anunciado desarrollos significativos en su tecnología ABBIE, revelando un cambio estratégico en su modelo de negocio. La empresa está transitando de la venta de kits ABBIE para uso independiente a establecer un modelo de licencias, aprovechando su cartera global de Propiedad Intelectual.
Los hallazgos innovadores de la empresa indican que la tecnología ABBIE presenta capacidades únicas de trazabilidad ausentes en tecnologías competidoras, lo que podría simplificar los procesos de aprobación de la FDA y mejorar la seguridad de las terapias. SOHM está actualmente en discusiones de diligencia técnica con pequeños innovadores y grandes empresas farmacéuticas, centrándose en aplicaciones en terapia CAR-T, desarrollo de medicamentos contra el cáncer y terapia génica.
La empresa planea publicar estos hallazgos en el segundo trimestre de 2025 y organizará seminarios en la plataforma para mostrar el potencial de la tecnología en la revolución del tratamiento del cáncer.
SOHM Inc (OTC PINK:SHMN)은 ABBIE 기술에서 중요한 발전을 발표하며 비즈니스 모델의 전략적 전환을 밝혔습니다. 이 회사는 독립적인 사용을 위한 ABBIE 키트 판매에서 라이센스 모델 수립으로 전환하고 있으며, 글로벌 지적 재산 포트폴리오를 활용하고 있습니다.
회사의 혁신적인 발견은 ABBIE 기술이 경쟁 기술에는 없는 독특한 추적 능력을 갖추고 있어 FDA 승인 과정을 간소화하고 치료의 안전성을 향상시킬 수 있음을 나타냅니다. SOHM은 현재 소규모 혁신가 및 대형 제약 회사와 기술 실사 논의를 진행 중이며, CAR-T 치료, 암 약물 개발 및 유전자 치료에 대한 응용에 집중하고 있습니다.
회사는 2025년 2분기에 이러한 발견을 발표할 계획이며, 기술의 잠재력을 보여주기 위해 플랫폼 세미나를 조직할 것입니다.
SOHM Inc (OTC PINK:SHMN) a annoncé des développements significatifs dans sa technologie ABBIE, révélant un pivot stratégique dans son modèle commercial. L'entreprise passe de la vente de kits ABBIE pour un usage indépendant à l'établissement d'un modèle de licence, tirant parti de son portefeuille mondial de propriété intellectuelle.
Les découvertes révolutionnaires de l'entreprise indiquent que la technologie ABBIE présente des capacités de traçabilité uniques absentes dans les technologies concurrentes, ce qui pourrait rationaliser les processus d'approbation de la FDA et améliorer la sécurité des thérapies. SOHM est actuellement en discussions de diligence technique avec des petits innovateurs et de grandes entreprises pharmaceutiques, en se concentrant sur des applications dans la thérapie CAR-T, le développement de médicaments contre le cancer et la thérapie génique.
L'entreprise prévoit de publier ces résultats au deuxième trimestre 2025 et organisera des séminaires sur la plateforme pour montrer le potentiel de la technologie à révolutionner le traitement du cancer.
SOHM Inc (OTC PINK:SHMN) hat bedeutende Entwicklungen in ihrer ABBIE-Technologie angekündigt und dabei einen strategischen Wandel in ihrem Geschäftsmodell offenbart. Das Unternehmen wechselt von der Verkauf von ABBIE-Kits für den unabhängigen Gebrauch zu einem Lizenzmodell und nutzt dabei sein globales Portfolio an geistigem Eigentum.
Die bahnbrechenden Erkenntnisse des Unternehmens zeigen, dass die ABBIE-Technologie einzigartige Rückverfolgbarkeitsfähigkeiten aufweist, die bei konkurrierenden Technologien fehlen, was potenziell die FDA-Zulassungsverfahren vereinfachen und die Sicherheit von Therapien verbessern könnte. SOHM befindet sich derzeit in technischen Due-Diligence-Gesprächen mit sowohl kleinen Innovatoren als auch großen Pharmaunternehmen und konzentriert sich auf Anwendungen in CAR-T-Therapie, Entwicklung von Krebsmedikamenten und Gentherapie.
Das Unternehmen plant, diese Erkenntnisse im zweiten Quartal 2025 zu veröffentlichen und wird Plattformseminare organisieren, um das Potenzial der Technologie zur Revolutionierung der Krebsbehandlung zu demonstrieren.
- Strategic pivot to licensing model potentially increases profit margins and recurring revenue
- Unique traceability feature provides competitive advantage in the market
- Ongoing discussions with major pharmaceutical companies indicate strong market interest
- Technology applications span multiple high-value sectors (CAR-T, cancer, gene therapy)
- Discontinuation of direct ABBIE kit sales may impact immediate revenue
- Success dependent on securing licensing partnerships
- No immediate revenue figures or partnership details disclosed
CHINO HILLS, CA / ACCESS Newswire / March 10, 2025 / SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, has announced today Groundbreaking findings in their ABBIE Technology.
Dr. David Aguilar, Chief Operating Officer, states that we are thrilled to share some exciting advancements in our ABBIE development and commercialization journey! Our team has made significant strides, leading us to refine our strategy for the future. After careful consideration, we have decided to pivot away from the sale and distribution of ABBIE kits for independent use. Instead, we are harnessing the power of our expanding global Intellectual Property portfolio to establish a strong and innovative licensing model.
This strategic shift enables us to focus our marketing and sales efforts on forging valuable licensing partnerships in the dynamic fields of CAR-T therapy, cancer drug development and gene therapy. We are currently engaged in in-depth technical diligence discussions with both small-scale innovators and major, globally positioned pharmaceutical companies, positioning ABBIE at the forefront of cutting-edge cancer research.
Our recent findings are particularly groundbreaking: ABBIE technology provides an inherent traceability component that is currently absent in competing technologies. This capability not only enhances the safety and control of therapies but also streamlines the process for FDA filings and approval requirements. We are on the brink of a new era in personalized medicine, where traceability will be a cornerstone of therapeutic efficacy and patient safety.
As we look to the future, we are excited to announce that we expect to publish our groundbreaking findings in the second quarter of 2025. Additionally, we are planning a series of platform seminars that will delve into the intricacies of our technology, showcasing its potential to revolutionize cancer treatment. The possibilities are boundless, and we are eager to continue this journey together, paving the way for transformative advancements in healthcare! Stay tuned for more updates as we embark on this thrilling path forward. Dr. Aguilar explained.
About SOHM, Inc.:
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy.
To learn more about SOHM, Inc., visit www.SOHM.com.
SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: info@sohm.com
Phone: (714) 522-6700
Safe Harbor Statement:
This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
SOURCE: SOHM, Inc
View the original press release on ACCESS Newswire
FAQ
What is the new business strategy for SOHM's ABBIE Technology (SHMN)?
What unique advantage does SOHM's ABBIE Technology offer compared to competitors?
When will SOHM (SHMN) publish their ABBIE Technology findings?
What potential partnerships is SOHM pursuing for ABBIE Technology?
